Enasidenib Plus Azacitidine vs Azacitidine Monotherapy in mIDH2 Newly Diagnosed Acute Myeloid Leukemia

May 29-31, 2020; Online at meetings.asco.org/am
Enasidenib plus azacitidine showed significantly improved response rates compared with azacitidine alone in patients with mIDH2 newly diagnosed acute myeloid leukemia.
Format: Microsoft PowerPoint (.ppt)
File Size: 264 KB
Released: June 4, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm Therapeutics

Related Content

In this commentary from Clinical Care Options (CCO), Dr. Jennifer Woyach discusses patient education and shared decision making in CLL

Jennifer Woyach, MD Released: November 17, 2021

A downloadable slideset from Clinical Care Options (CCO) on current management of AML tailored for nurses and physician assistants.

Released: November 11, 2021

Gain key clinical insights quickly with this short slideset from CCO on new advances using BTK inhibitors in the treatment of CLL.

person default Seema Ali Bhat, MD Talha Munir, MBBS, MRCP, FRCPath Released: November 4, 2021

Expert commentary on managing patients with CML and comorbidities, from Clinical Care Options (CCO)

Jorge Cortes, MD Released: November 3, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue